Donepezil Hydrochloride
Product Images NDC 42658-130

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Donepezil Hydrochloride (NDC 42658-130). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Hisun Pharmaceuticals Usa, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

8088a70f-figure-01 (8088a70f Figure 01)

Chemical structure of Donepezil Hydrochloride showing its molecular framework with aromatic rings, methoxy groups, and a piperidine ring linked to a benzyl group, alongside the HCl component.*

FDA Label Image

S:\clients\abon Pharmaceuticals Llc\donepezil HCl Tablets\2016-apr Labeling Response\figure1.jpg (8088a70f Figure 02)

A line graph showing the ADAS-cog change from baseline mean (±SE) over 24 weeks of drug treatment comparing Donepezil Hydrochloride at 10 mg/day, 5 mg/day, and placebo. The graph indicates clinical improvement versus decline, with Donepezil groups showing less cognitive decline compared to placebo.*

FDA Label Image

S:\clients\abon Pharmaceuticals Llc\donepezil HCl Tablets\2016-apr Labeling Response\figure2.jpg (8088a70f Figure 03)

A cumulative percentage of patients graph showing change from baseline in ADAS-cog scores for Donepezil Hydrochloride 5 mg/day, 10 mg/day, and placebo groups. The x-axis measures change from baseline, while the y-axis depicts cumulative patient percentage. The graph includes labeled points at -7, -4, and 0 changes, illustrating greater improvements in the Donepezil Hydrochloride groups compared to placebo.*

FDA Label Image

S:\clients\abon Pharmaceuticals Llc\donepezil HCl Tablets\2016-apr Labeling Response\figure3.jpg (8088a70f Figure 04)

A bar chart showing the distribution of CIBIC-plus ratings for patients treated with Donepezil Hydrochloride at 5 mg/day and 10 mg/day doses compared to placebo. The chart plots the percentage of patients against rating categories from Markedly Improved to Markedly Worse, illustrating treatment outcomes in different groups.*

FDA Label Image

S:\clients\abon Pharmaceuticals Llc\donepezil HCl Tablets\2016-apr Labeling Response\figure4.jpg (8088a70f Figure 05)

A line graph showing ADAS-cog mean change from baseline over weeks of drug treatment comparing Donepezil Hydrochloride 10 mg/day, 5 mg/day, and placebo. The y-axis measures cognitive change with negative values indicating improvement and positive values indicating decline. Data points with error bars track changes through 12 weeks of treatment and an additional placebo phase up to 15 weeks.*

FDA Label Image

S:\clients\abon Pharmaceuticals Llc\donepezil HCl Tablets\2016-apr Labeling Response\figure5.jpg (8088a70f Figure 06)

A line graph showing the cumulative percentage of patients versus change from baseline tracking cognitive function in three groups: Donepezil Hydrochloride 10 mg/day, 5 mg/day, and placebo. The x-axis measures change from baseline with markers for 7 point improvement, 4 point improvement, and no change. The y-axis shows cumulative percentage of patients up to 100%. A table inset presents the percentage of patients by treatment group experiencing changes of -7, -4, and 0 points in ADAS-cog scores.*

FDA Label Image

S:\clients\abon Pharmaceuticals Llc\donepezil HCl Tablets\2016-apr Labeling Response\figure6.jpg (8088a70f Figure 07)

A bar chart showing the distribution of patients' CIBIC-plus ratings comparing Donepezil Hydrochloride at 10 mg/day, 5 mg/day, and placebo. The vertical axis represents the percentage of patients, and the horizontal axis categorizes ratings from Markedly Improved to Markedly Worse, illustrating patient response across the three groups.*

FDA Label Image

S:\clients\abon Pharmaceuticals Llc\donepezil HCl Tablets\2016-apr Labeling Response\figure7.jpg (8088a70f Figure 08)

A line graph depicting SIB (Severe Impairment Battery) change from baseline over 6 months of drug treatment comparing Donepezil Hydrochloride 10 mg/day and Placebo. The graph shows mean change with standard error bars, with Donepezil Hydrochloride demonstrating clinical improvement and Placebo trending towards clinical decline.*

FDA Label Image

S:\clients\abon Pharmaceuticals Llc\donepezil HCl Tablets\2016-apr Labeling Response\figure8.jpg (8088a70f Figure 09)

A cumulative percentage of patients graph comparing Donepezil hydrochloride 10 mg/day to placebo. The x-axis represents SIB (Severe Impairment Battery) change from baseline, ranging approximately from +30 to -75. The y-axis shows cumulative patient percentages from 0 to 100%. Two lines display results, with Donepezil hydrochloride indicated by filled circles and placebo by open squares.*

FDA Label Image

S:\clients\abon Pharmaceuticals Llc\donepezil HCl Tablets\2016-apr Labeling Response\figure9.jpg (8088a70f Figure 10)

Line graph showing the ADCS-ADL change from baseline over 6 months of drug treatment comparing Donepezil Hydrochloride 10 mg/day and placebo. The y-axis indicates clinical improvement or decline, with Donepezil showing less decline than placebo over time.*

FDA Label Image

S:\clients\abon Pharmaceuticals Llc\donepezil HCl Tablets\2016-apr Labeling Response\figure10.jpg (8088a70f Figure 11)

A line graph comparing cumulative percentage of patients versus ADCS-ADL change from baseline. It shows two curves representing donepezil hydrochloride 10 mg/day and placebo, illustrating patient response differences over a range of ADCS-ADL changes.*

FDA Label Image

S:\clients\abon Pharmaceuticals Llc\donepezil HCl Tablets\2016-apr Labeling Response\figure11.jpg (8088a70f Figure 12)

A line graph depicting SIB (Severe Impairment Battery) change from baseline over 24 weeks of drug treatment with Donepezil Hydrochloride at doses of 23 mg/day and 10 mg/day. The graph shows mean changes with standard error, illustrating clinical improvement or decline relative to baseline for each dose over time.*

FDA Label Image

S:\clients\abon Pharmaceuticals Llc\donepezil HCl Tablets\2016-apr Labeling Response\figure12.jpg (8088a70f Figure 13)

A cumulative percentage graph comparing patient responses to Donepezil Hydrochloride at 10 mg/day and 23 mg/day dosages. The x-axis shows SIB change from baseline ranging from 50 to -60, and the y-axis shows cumulative percentage of patients from 0 to 100%. Two lines represent the two dosage groups, illustrating their cumulative distribution of SIB score changes.*

FDA Label Image

S:\clients\abon Pharmaceuticals Llc\donepezil HCl Tablets\2016-apr Labeling Response\figure13.jpg (8088a70f Figure 14)

A bar chart showing the distribution of CIBIC-plus ratings among patients taking Donepezil Hydrochloride at 10 mg/day and 23 mg/day doses. The x-axis lists categories from Markedly Improved to Markedly Worse; the y-axis represents the percentage of patients. Both doses show similar patterns with most patients in the No Change and Minimally Worse categories.*

FDA Label Image

C:\users\admin\desktop\donepezil Spl\label-90ct.jpg (8088a70f Figure 15)

Label for Donepezil Hydrochloride Tablets, USP 23 mg, by Hisun Pharmaceuticals USA, Inc. The label indicates each film-coated tablet contains 23 mg donepezil hydrochloride. The package contains 90 tablets, labeled Rx only. Distributed by Hisun Pharmaceuticals USA, Inc., Bridgewater, NJ, and manufactured by QS Pharma, LLC, Boothwyn, PA. Includes storage instructions and a barcode.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.